

1 **Lower Risks of Incident Colorectal Cancer in SGLT2i Users Compared to DPP4i Users: A**
2 **Propensity Score-matched Study with Competing Risk Analysis**

3 **Running Title:** SGLT2i Reduces Risk of Incident Colorectal Cancer

4 **Keywords:** Diabetes mellitus; colorectal cancer; SGLT2 inhibitors; DPP4 Inhibitors

5

6 Raymond Ngai Chiu Chan ¹, Robert Ngai Fung Chan ¹, Oscar Hou In Chou ¹, Teddy Tai Loy Lee ¹,
7 Leonardo Roever MHS PhD ², Guoliang Li MD PhD ³, Wing Tak Wong PhD ⁴, Abraham Ka Chung
8 Wai MBChB FRCP ⁵, Tong Liu MD PhD ⁶, Gary Tse MD PhD FRCP FFPH FRCPATH # ^{1,6,7}, Sharen
9 Lee MBChB # ¹

10 ¹ Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

11 ² Department of Clinical Research, Federal University of Uberlandia, Uberlândia, Brazil

12 ³ Department of Cardiology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an,
13 China

14 ⁴ School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China

15 ⁵ Department of Emergency Medicine, School of Clinical Medicine, University of Hong Kong,
16 Hong Kong, China

17 ⁶ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
18 Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University,
19 Tianjin 300211, China

20 ⁷ Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK

21

22 **# Correspondence to:**

23 Gary Tse, MD PhD FRCP FFPH FRCPATH

24 Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

25 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
26 Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin
27 300211, China

28 Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK

29 Email: gary.tse@kmms.ac.uk

30 Tel: +44 7309321109

31

32 Sharen Lee, MBChB

33 Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

34 Email: sharen212@gmail.com

35

36 **Contribution of Authors**

37 RNCC and RNFC are responsible for study concept and design, analysis and interpretation of data,
38 drafting the manuscript, and statistical analysis. OHIC is responsible for study concept and design, as
39 well as acquisition of data. TTLL, LR, GL, WTW, AKCW, TL are responsible for study concept and
40 design, as well as critical revision of the manuscript for important intellectual content. GT and SL are
41 responsible for study concept and design, critical revision of the manuscript for important intellectual
42 content, and study supervision.

43

44 **Conflict of Interest**

45 None.

46

47 **Financial Support**

48 None.

49

50 **Abstract**

51 **Background:** Diabetes mellitus is associated with the development of colorectal cancer (CRC).

52 There have been a lack of study comparing the risk of colorectal cancer in sodium-glucose co-
53 transporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i), both of which
54 commonly prescribed second line agents for diabetes.

55 **Methods:** We conducted a territory wide retrospective cohort study on patients with type 2 diabetes
56 who was prescribed either of the two agents. Baseline demographics, use of other medications,
57 comorbidities and biochemical parameters were extracted. Propensity score matching was performed
58 to reduce the impacts of cofounders. Cause specific Cox regression was used to evaluate the risk of
59 incident colorectal cancer in SGLT2i users, as compared to DPP4i users. Subgroup analyses based
60 on age, gender and estimated glomerular filtration rate were performed.

61 **Results:** After propensity score matching, we included 13029 subjects who were prescribed SGLT2i
62 and DPP4i respectively. Incidence rate ratio of CRC was 0.566 (0.418-0.766) in SGLT2i users.
63 Overall, use of SGLT2i was associated with a lower risk of incident CRC (HR: 0.526; 95% CI:
64 0.382-0.724; P <0.001). In subgroup analyses, use of SGLT2i was associated with lower risks of
65 incident CRC only in men (HR: 0.461; 95% CI: 0.303-0.702; P <0.001), patients < 65 years old and
66 patients (HR:0.294; 95% CI: 0.174-0.496; P<0.001) with eGFR \geq 45 mL/min/ 1.73m² (HR: 0.560;
67 95% CI: 0.395-0.792; P =0.001).

68 **Conclusion:** Use of SGLT2i may reduce risk of incident CRC as compared to use of DPP4i,
69 especially in younger male patients with fairly preserved renal function.

70

71 **INTRODUCTION**

72 Diabetes mellitus is a global public health issue affecting 536.6 million people worldwide in
73 2021 ¹. Previous studies have established clear epidemiological links between diabetes mellitus and
74 various co-morbidities, including malignancies like liver, pancreatic, endometrial and colorectal
75 cancers (CRC) ^{2,3}. A meta-analysis in 2013, which pooled data from 20 controlled trials and cohort
76 studies after 2007, reported a higher risk of incident CRC as well as a higher CRC-specific mortality
77 in diabetic patients ⁴. Several groups have investigated the effects of anti-diabetic medications on the
78 risk of CRC. Metformin, an oral anti-hyperglycemic agent recommended by the American Diabetes
79 Association as the preferred initial pharmacologic treatment for type 2 diabetes mellitus (T2DM),
80 was found to have a protective effect on incident CRC by several studies ⁵⁻⁷, although conflicting
81 results have been generated by other groups ⁸⁻¹¹. The effects of newer anti-diabetic medications,
82 especially dipeptidyl peptidase 4 inhibitors (DPP4i) and sodium-glucose co-transporter 2 inhibitors
83 (SGLT2i), were less studied.

84 DPP4i and SGLT2i are two emerging drug classes approved by the FDA for the treatment of
85 T2DM ¹². Given the protective effects of DPP4i on pancreatic beta cells function, as well as the
86 cardioprotective and renoprotective effects of SGLT2i, both are increasingly prescribed as second
87 line treatment for T2DM ¹³⁻¹⁶. Preclinical studies on DPP4i and SGLT2i have highlighted their
88 potentials in CRC suppression ¹⁷⁻¹⁹. Although there are few studies evaluating the effects of DPP4i
89 on CRC, most of them were of small scale and none directly compared it with SGLT2i ²⁰. Whether
90 any of these agents could alter the risk of incident CRC in T2DM patients remains unclear. Hence in
91 the present study, we aim to compare the risk of incident CRC in DPP4i and SGLT2i users amongst
92 T2DM patients using a large territory wide cohort in Hong Kong.

93

94 **METHODS**

95 *Study design and population*

96 This was a territory-wide retrospective cohort study in T2DM patients treated with SGLT2i
97 or DPP4i between January 1st, 2016, and December 31st, 2019 in Hong Kong. Patients were
98 followed up until December 31st, 2020, or death, whichever came earlier. The current study was
99 approved by The Joint Chinese University of Hong Kong–New Territories East Cluster Clinical
100 Research Ethics Committee. Subjects were identified from the Clinical Data Analysis and Reporting
101 System (CDARS) of the Hospital Authority in Hong Kong. It is a territory-wide database that
102 centralizes patient information from all public hospitals and clinics in Hong Kong, which facilitates
103 retrieval of clinical characteristics, disease diagnosis, laboratory results and drug treatment details. It
104 has been used by local teams in Hong Kong to conduct studies on T2DM²¹⁻²³, and recently by our
105 team comparing the cardiovascular outcomes between SGLT2I and DPP4I users²⁴⁻²⁶.

106 Patients were excluded if any of the following criteria were met: 1) less than one year of drug
107 exposure; 2) on both DPP4I and SGLT2I, or switched between the two drug classes; 3) died within
108 30 days after initial drug exposure; 4) less than 18 years old at the start of the study; 5) pregnancy; 6)
109 without complete demographics 7) with no HbA1c records at baseline; 8) with a history of colorectal
110 cancer prior to baseline.

111 Patients' demographics, clinical and biochemical data were extracted for the present study.
112 Comorbidities at baseline were defined and extracted using the International Classification of
113 Diseases Ninth Edition (ICD-9) codes (**Supplementary Table 1**). Charlson's standard comorbidity
114 index was calculated. Use of anti-diabetic and lipid-lowering agents were extracted. Baseline
115 biochemistry, including the complete blood count, renal function tests, liver function tests, lipid and
116 glycemic profiles were extracted. Estimated glomerular filtration rate (eGFR) was calculated by the
117 abbreviated modification of diet in renal disease (MDRD) formula²⁷.

118

119 *Adverse outcomes and statistical analysis*

120 The primary endpoint of the present study was incident colorectal cancer (ICD-9: 153-154).

121 Mortality data were obtained from the Hong Kong Death Registry, a population-based official
122 government registry with the registered death records of all Hong Kong citizens linked to CDARS.
123 The endpoint date of interest for eligible patients was the event presentation date. The endpoint for
124 those without primary outcome presentation was the mortality date or the endpoint of the study
125 (December 31st, 2020).

126 For baseline clinical characteristics, continuous and categorical variables were presented as
127 mean (standard deviation [SD]) and frequency (percentage) respectively. Propensity score matching
128 (PSM) with a 1:1 ratio for SGLT2i users versus DPP4i users based on age, gender, Charlson's
129 comorbidity index, other comorbidities and non-SGLT2I/ DPP4I medications was performed using
130 the nearest neighbor search strategy. Baseline characteristics between patients with SGLT2i and
131 DPP4i use before and after matching were compared with standardized mean difference (SMD), with
132 $SMD < 0.20$ regarded as well-balanced. The incidence of new-onset colorectal cancer was derived
133 from dividing the number of outcomes by person-year at risks, which estimate the number of years at
134 risks. Cause specific hazard models were used to calculate the unadjusted and adjusted hazard ratios.
135 Important covariates were adjusted by backward selection. HDL was considered as a surrogate
136 marker of BMI and was adjusted in addition to other covariates. It has been shown to correlate better
137 with BMI as compared to other serum lipids²⁸⁻³¹. Fine Gray's subdistribution hazard models were
138 conducted as sensitivity analyses. Subgroup analyses were performed in patients ≥ 65 years old, < 65
139 years old, male and female. We aimed to evaluate the impact of renal function on the effects of
140 SGLT2i and/or DPP4i, hence subgroup analyses were also performed in patients with $eGFR \geq 45$
141 $mL/min/1.73m^2$ and $< 45 mL/min/1.73m^2$ respectively. The hazard ratios (HR), 95% CI and P-value
142 were reported. Statistical significance was taken as $P\text{-value} < 0.05$. All statistical analyses were
143 performed with RStudio software (Version: 1.1.456).

144

145 **RESULTS**

146 *Baseline characteristics of the study population*

147 In this retrospective cohort study, 86 353 patients in Hong Kong using SGLT2i/DPP4i
148 between January 1st, 2016 and December 31st, 2019 were recruited. They were followed up until
149 December 31st, 2020 or deaths, which ever came earlier. Patients with less than one month of drug
150 exposure (n = 3019), on both DPP4i and SGLT2i (n = 13529), died within 30 days after initial drug
151 exposure (n = 4491), less than 18 years old at baseline (n = 592), less than 1 year of drug exposure (n
152 = 1781), pregnancy (n = 19), without complete demographics or mortality data (n = 15), without
153 baseline HbA1c (n = 9766), with CRC prior to baseline (n = 289) were excluded.

154 Subsequently, 18 741 SGLT2i users and 33 839 DPP4i users were included. After 1:1
155 propensity score matching, 13 029 patients on SGLT2i and DPP4i respectively entered statistical
156 analyses. In the matched cohort, 65 (0.5%) SGLT2i users and 118 (0.9%) DPP4i users developed
157 incident CRC. The baseline characteristic of patients before and after PSM are shown in
158 **Supplementary Table 2 and Table 1** respectively.

159

160 *SGLT2i use is associated with reduced risk of incident CRC*

161 Over a follow-up period of 117734.1 person-years, 183 incident CRC were identified.
162 Overall, the incidence of CRC (IRR: 0.566; 95% CI: 0.418-0.766; P<0.001) were lower amongst
163 SGLT2i users compared to DPP4i users after PSM (**Table 2**). We used univariable Cox regression to
164 identify the potential risk factors of incident CRC before and after PSM, which were serially adjusted
165 in subsequent multivariable models (**Supplementary Table 3 and 4**). Unadjusted and adjusted
166 hazard ratios for incident CRC were presented in **Table 3**. In all models, use of SGLT2i was
167 significantly associated with lower risks of incident CRC as compared to use of DPP4i. After
168 adjusting for age, gender, HbA1c, use of other medications, comorbidities and HDL, use of SGLT2i
169 was associated with an approximately 47.4% reduction in the risk of incident CRC (HR: 0.526; 95%
170 CI: 0.382-0.724; P<0.001).

171 Sensitivity analyses were performed using Fine-Gray's subdistribution regression model to
172 confirm the predictiveness of the models. Similarly, use of SGLT2i was associated with lower risks
173 of incident CRC in the sensitivity analyses after serial adjustment of important covariates identified
174 in univariable analyses (**Supplementary Table 5**). In model 5, use of SGLT2i was associated with a
175 42.5% reduction in risk of incident CRC (HR: 0.575; 95% CI: 0.368-0.896; P= 0.015).

176

177 *Effects of SGLT2i on the risk of incident CRC stratified by age and gender*

178 Sub-group analyses based on age and gender were further performed. In male, use of SGLT2i
179 was associated with lower risks of incident CRC (HR: 0.461; 95% CI: 0.303-0.702; P <0.001) but no
180 significant association was found in female (**Table 4**). Similar results were reproduced in the
181 sensitivity analyses using Fine-Gray's subdistribution hazard models (HR: 0.505; 95% CI: 0.339-
182 0.752; P <0.001) (**Supplementary Table 6**). In patients younger than 65 years old, use of SGLT2i
183 was associated with reduced risks of incident CRC (HR: 0.294; 95% CI: 0.174-0.496; P <0.001)
184 whereas no significant association was found in the older group (**Table 5**). Again, similar results
185 were observed in sensitivity analyses (HR: 0.328; 95% CI: 0.198-0.546; P<0.001). (**Supplementary**
186 **Table 7**)

187

188 *Effects of SGLT2i on the risk of incident CRC stratified by eGFR*

189 To assess the impact of eGFR on the effects of SGLT2i, we conducted subgroup analyses
190 based on the eGFR. As the number of incident CRC in patients with eGFR < 45 mL/min/ 1.73m² is
191 inadequate to perform a robust analysis, the unmatched cohort were used. In patients with eGFR ≥ 45
192 mL/min/ 1.73m², use of SGLT2i was correlated with a significantly reduced risk of incident CRC
193 (HR: 0.560; 95% CI: 0.395-0.792; P = 0.001). However, in patients with more advanced CKD, the
194 association was lost. (**Table 6**) Sensitivity analyses yielded similar findings (**Supplementary Table**
195 **8**).

196

197 *SGLT2i use is associated with lower all-cause mortality in patients who developed incident CRC*

198 We compared the all-cause mortality of patients with incident CRC amongst SGLT2i and DPP4i
199 users. Given the limited number of deaths with incident CRC in the matched cohort, the analyses
200 were, again, performed in the unmatched cohort. Use of SGLT2i was not associated with lower risks
201 of all-cause mortality (HR: 0.285; 95% CI: 0.066-1.25; P = 0.097) after adjusted for age, gender
202 HbA1c, use of medications, and comorbidities (**Supplementary Table 9**).

203

204 **DISCUSSION**

205 In the present study, we used a territory-wide cohort to compare the risk of incident CRC
206 amongst SGLT2i and DPP4i users. To our knowledge, this is the first study thus far to evaluate the
207 incidence of CRC amongst patients treated with the named medications. Importantly, we were able
208 to demonstrate several clinically relevant findings: 1) use of SGLT2i was associated with a lower
209 risk of incident CRC after serial adjustment. 2) The effects of SGLT2i on incident CRC, as compared
210 to DPP4i, differ with respect to patients' age, gender and renal function. 3) Use of SGLT2i may not
211 reduce all-cause mortality in DM patients with incident CRC. These findings are of clinical
212 significance as SGLT2i and DPP4i are both commonly prescribed second line pharmacological
213 treatment for T2DM.

214

215 *SGLT2i Reduce Risk of Incident CRC via an eGFR-Dependent Pathway*

216 Diabetes mellitus and insulin resistance have been recognized to be major risk factors of
217 various malignancies including CRC, although the exact mechanism remains unclear^{2, 3}.
218 Hyperinsulinemia, which characterizes pre-diabetes and early diabetes, was known to promote
219 cancer cell survival and mitogenesis via binding to insulin and insulin-like growth factor (IGF)
220 receptors that are widely expressed on cancer cells membrane³²⁻³⁴. Other mechanisms, such as

221 upregulation of inflammatory cytokines, alterations of cellular energetics and shared risk factors,
222 have previously been proposed ^{2, 35}. In view of the epidemiological and biological links between
223 CRC and diabetes mellitus, studies have investigated the relationship between different anti-diabetic
224 medications and incident CRC.

225 Currently, there is a lack of evidence on the effects of SGLT2i, a relatively new agent for
226 T2DM that inhibits SGLT2 in the kidney to promote glycosuria, on incident CRC ³⁶. In contrary to
227 most anti-diabetic medications, its major mechanism of action is independent of insulin. Studies
228 suggested that use of SGLT2i improved insulin sensitivity and potentially lowers plasma insulin
229 level ^{37, 38}. Preclinical animal models echoed this finding by showing a dramatically reduced plasma
230 insulin in SGLT2 knockout mice ³⁹. Furthermore, use of SGLT2i has been shown to improve shared
231 risk factors between CRC and diabetes, reduce circulating inflammatory cytokines, attenuate
232 vascular endothelial and smooth muscle cells proliferation in response to interleukins, alter cellular
233 energetics and suppress oxidative stress, all of which may be protective factors against malignancies
234 such as CRC ^{37, 40-42}. However, whether SGLT2i reduces risk of incident CRC and the actual
235 mechanisms, if any, remain unknown.

236 In the present study, we demonstrated that SGLT2i significantly reduced the risk of incident
237 CRC, and the association was only significant when the eGFR was ≥ 45 mL/min/ 1.73m².
238 Apparently, the glycosuria effects of SGLT2i depends on relatively preserved glomerular function. A
239 previous study suggested that the glucose lowering effect of SGLT2i was attenuated when the eGFR
240 dropped to < 45 mL/min/ 1.73m², while another suggested that the effect was lost when the eGFR
241 dropped to < 30 mL/min/ 1.73m² ^{43, 44}. In our study, we were able to demonstrate that the protective
242 effect of SGLT2i against incident CRC, as compared to DPP4i, was independent of glycemic control
243 by adjusting for HbA1c, but the association was lost when the eGFR was below 45 mL/min/ 1.73m².
244 Hence, it is reasonable to hypothesize that SGLT2i may reduce the risk of incident CRC via its
245 glycosuria effect, which reduces circulating insulin level at any given blood glucose level and

246 downregulates farnesylated Ras protein to suppress mitogenesis⁴⁵. Although the role of chronic
247 inflammation and SGLT2 expression on CRC cell lines has been previously implicated, a recent
248 study showed that oral administration of SGLT2i in obese and diabetic mice with azoxymethane-
249 induced colorectal pre-neoplastic lesions appeared to reduce IGF-1 and several related signaling
250 molecules in the colonic mucosa, while direct administration of SGLT2i on human CRC cell lines
251 exhibited no impacts on cellular proliferation, further supporting our hypothesis⁴⁶. Further
252 investigations are warranted to validate these findings.

253

254 *Differential effects of SGLT2i across gender and age*

255 In the present study, we also demonstrated that SGLT2i only reduced risk of incident CRC in
256 male and younger patients, but not their female or older counterparts. In fact, gender dimorphism in
257 CRC in terms of the incidence, molecular pathogenesis and prognosis have been previously reported
258^{47,48}. Lifestyle factors, hormonal differences, and more recently single nucleotide polymorphisms or
259 genetic variants have been proposed to explain these differences⁴⁹⁻⁵².

260

261 Several epidemiological studies have suggested that the relationship between obesity and CRC is
262 stronger in male than female, potentially due to the fact the protective effect of estrogen over insulin
263 resistance and subsequent hyperinsulinemia⁵³⁻⁵⁷. Recent studies also suggested the insulin-IGF axis
264 is preferentially upregulated in men with CRC^{58,59}. Differences in the level and biological action of
265 insulin and IGF across the two genders may potentially account for the discrepancy. Meanwhile,
266 elderly patients with T2DM may have relatively less preserved pancreatic β -cell function and renal
267 function while insulin sensitivity appeared to be similar in older and younger subjects with
268 comparable BMI⁶⁰⁻⁶². These may limit the effects of SGLT2i on preventing incident CRC.

269

270 *Strengths and limitations*

271 With the use of medical records from a territory-wide database, CDARS, our study was able
272 to detect relatively rare outcomes, such as incident CRC, with an adequate sample size and follow-up
273 duration. The present study was also the first to compare the difference in CRC incidence amongst
274 T2DM patients treated with SGLT2i and DPP4i. Subgroup analyses in our study may also provide
275 mechanistic insight into the anti-tumour effects of SGLT2i. However, there are still certain limitation
276 in our study. First, although CDARS has been considered a relatively reliable source of clinical data,
277 there was unavoidably information bias due to the risk of under-coding, coding errors and missing
278 data. Second, BMI has been considered an important risk factor of CRC but was not available in our
279 database. The use of HDL as a surrogate marker may potentially and partially adjust for this
280 limitation. Third, the retrospective nature of our study did not allow measurement of drug
281 concentration, which might correlate with the outcomes. Fourth, the present study aimed at assessing
282 the epidemiological links between use of SGLT2i and DPP4i with incident CRC and could not
283 address the causal or mechanistic relationship. Lastly, SGLT2I and DPP4I are drug classes
284 constituting a variety of agents from different brands with their respective formula. The present study
285 did not conduct further analyses to compare the effects of different agents in the same drug class.

286

287 **CONCLUSION**

288 SGLT2i use is associated with a reduced risk of incident CRC compared to DPP4i use. The
289 association was significant only in younger patients, male and in patients with an eGFR ≥ 45
290 mL/min/ 1.73m^2 . SGLT2i use was not associated with a lower all-cause mortality in diabetic patients
291 with incident CRC. Further studies are warranted to validate the findings.

292

ACKNOWLEDGEMENTS

Nil

CONFLICT OF INTEREST

Nil

FUNDING

Nil

REFERENCES

1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 2022;183:109119.
2. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and Cancer: A consensus report. *Diabetes Care* 2010;33:1674-1685.
3. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. *Endocr Relat Cancer* 2009;16:1103-23.
4. De Bruijn KM, Arends LR, Hansen BE, et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. *Br J Surg* 2013;100:1421-9.
5. Sehdev A, Shih YC, Vekhter B, et al. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. *Cancer* 2015;121:1071-8.
6. Chang YT, Tsai HL, Kung YT, et al. Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes- A Nationwide Cohort Study. *Transl Oncol* 2018;11:535-541.
7. Rennert G, Rennert HS, Gronich N, et al. Use of metformin and risk of breast and colorectal cancer. *Diabetes Res Clin Pract* 2020;165:108232.
8. Spillane S, Bennett K, Sharp L, et al. Metformin exposure and disseminated disease in patients with colorectal cancer. *Cancer Epidemiology* 2014;38:79-84.
9. Shin CM, Kim N, Han K, et al. Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study. *Cancer Epidemiology* 2020;64:101658.
10. Cardel M, Jensen SM, Pottegard A, et al. Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. *Cancer Med* 2014;3:1458-66.
11. Lin CM, Huang HL, Chu FY, et al. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. *PLoS One* 2015;10:e0125421.
12. Ferro EG, Michos ED, Bhatt DL, et al. New Decade, New FDA Guidance for Diabetes Drug Development. *Journal of the American College of Cardiology* 2020;76:2522-2526.
13. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol* 2020;16:642-653.

14. Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. *Circulation* 2017;136:1643-1658.
15. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation* 2016;134:752-72.
16. Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. *Am J Kidney Dis* 2018;72:267-277.
17. Nasiri AR, Rodrigues MR, Li Z, et al. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. *Cancer & Metabolism* 2019;7:10.
18. Kato J, Shirakami Y, Ohnishi M, et al. Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. *Oncol Rep* 2019;42:2797-2805.
19. Amritha CA, Kumaravelu P, Chellathai DD. Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study. *J Clin Diagn Res* 2015;9:Fc14-6.
20. Overbeek JA, Bakker M, van der Heijden A, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. *Diabetes Metab Res Rev* 2018;34:e3004.
21. Lee S, Liu T, Zhou J, et al. Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study. *Acta Diabetol* 2021;58:171-180.
22. Lee S, Zhou J, Guo CL, et al. Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death. *Endocrinol Diabetes Metab* 2021;4:e00240.
23. Lee S, Jeevaratnam K, Liu T, et al. Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population-based cohort study. *Clin Cardiol* 2021;44:1602-1612.
24. Lee S, Zhou J, Leung KSK, et al. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. *Cardiovasc Drugs Ther* 2022.
25. Zhou J, Lee S, Leung KSK, et al. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. *ESC Heart Fail* 2022;9:1388-1399.
26. Mui JV, Zhou J, Lee S, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis. *Front Cardiovasc Med* 2021;8:747620.
27. Soliman AR, Fathy A, Khashab S, et al. Comparison of abbreviated modification of diet in renal disease formula (aMDRD) and the Cockcroft-Gault adjusted for body surface (aCG) equations in stable renal transplant patients and living kidney donors. *Ren Fail* 2013;35:94-7.
28. Erem C, Hacıhasanoglu A, Deger O, et al. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. *Endocrine* 2008;34:36-51.
29. Stepien A, Stepien M, Wlazel RN, et al. Assessment of the relationship between lipid parameters and obesity indices in non-diabetic obese patients: a preliminary report. *Med Sci Monit* 2014;20:2683-8.
30. Boyd GS, Koenigsberg J, Falkner B, et al. Effect of obesity and high blood pressure on plasma lipid levels in children and adolescents. *Pediatrics* 2005;116:442-6.

31. Kucukhuseyin O, Kurnaz O, Akadam-Teker AB, et al. The association of MTHFR C677T gene variants and lipid profiles or body mass index in patients with diabetic and nondiabetic coronary heart disease. *J Clin Lab Anal* 2013;27:427-34.
32. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. *Cancer Res* 2007;67:391-7.
33. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. *Cell Commun Signal* 2009;7:14.
34. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. *J Nutr* 2001;131:3109S-20S.
35. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 2009;324:1029-33.
36. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. *Curr Opin Endocrinol Diabetes Obes* 2017;24:73-79.
37. Xu L, Nagata N, Nagashimada M, et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. *EBioMedicine* 2017;20:137-149.
38. Yaribeygi H, Sathyapalan T, Maleki M, et al. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. *Life Sci* 2020;240:117090.
39. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. *Diabetes* 2011;60:890-8.
40. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. *Diabetes Metab* 2018;44:457-464.
41. Sukhanov S, Higashi Y, Yoshida T, et al. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion. *Cell Signal* 2021;77:109825.
42. Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. *Sci Rep* 2018;8:5276.
43. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. *Kidney Int* 2014;85:962-71.
44. Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. *Kidney Int* 2018;93:231-244.
45. Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. *Diabetol Metab Syndr* 2011;3:10.
46. Kato J, Shirakami Y, Ohnishi M, et al. Suppressive effects of the sodiumglucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. *Oncol Rep* 2019;42:2797-2805.
47. Yang Y, Wang G, He J, et al. Gender differences in colorectal cancer survival: A meta-analysis. *Int J Cancer* 2017;141:1942-1949.

48. White A, Ironmonger L, Steele RJC, et al. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. *BMC Cancer* 2018;18:906.
49. Tan SC, Suzairi MS, Aizat AA, et al. Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer. *Med Oncol* 2013;30:693.
50. Martinelli M, Scapoli L, Cura F, et al. Colorectal cancer susceptibility: apparent gender-related modulation by ABCB1 gene polymorphisms. *J Biomed Sci* 2014;21:89.
51. Conti L, Del Corno M, Gessani S. Revisiting the impact of lifestyle on colorectal cancer risk in a gender perspective. *Crit Rev Oncol Hematol* 2020;145:102834.
52. Nussler NC, Reinbacher K, Shanny N, et al. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. *Gend Med* 2008;5:209-17.
53. West DW, Slattery ML, Robison LM, et al. Dietary intake and colon cancer: sex- and anatomic site-specific associations. *Am J Epidemiol* 1989;130:883-94.
54. Mao Y, Pan S, Wen SW, et al. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. *Int J Cancer* 2003;105:831-7.
55. Slattery ML, Caan BJ, Potter JD, et al. Dietary energy sources and colon cancer risk. *Am J Epidemiol* 1997;145:199-210.
56. Morimoto LM, Newcomb PA, White E, et al. Insulin-like growth factor polymorphisms and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2005;14:1204-11.
57. De Paoli M, Zakharia A, Werstuck GH. The Role of Estrogen in Insulin Resistance: A Review of Clinical and Preclinical Data. *Am J Pathol* 2021;191:1490-1498.
58. Zeljkovic A, Mihajlovic M, Stefanovic A, et al. Potential use of serum insulin-like growth factor 1 and E-cadherin as biomarkers of colorectal cancer. *Colorectal Dis* 2020;22:2078-2086.
59. Yamaji T, Iwasaki M, Sasazuki S, et al. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia. *Int J Obes (Lond)* 2012;36:440-7.
60. Bellary S, Kyrou I, Brown JE, et al. Type 2 diabetes mellitus in older adults: clinical considerations and management. *Nat Rev Endocrinol* 2021;17:534-548.
61. Amati F, Dube JJ, Coen PM, et al. Physical inactivity and obesity underlie the insulin resistance of aging. *Diabetes Care* 2009;32:1547-9.
62. Karakelides H, Irving BA, Short KR, et al. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. *Diabetes* 2010;59:89-97.




Figure 1: Flow Diagram for Subjects Selection and Propensity Score Matching

Characteristics	SGLT2I Users	DPP4I Users	SMD
Demographic			
Male	7350 (56.4)	7122 (54.7)	0.035
Age	60.4 (10.8)	61.2 (11.2)	0.073
Follow-up Duration	1810 (104)	1770 (205)	
Charlson's Score	1.81 (1.26)	1.87 (1.33)	0.043
Microvascular Complications			
Diabetic Retinopathy	795 (6.10)	693 (5.32)	0.034
Diabetic Nephropathy	8454 (64.9)	8497 (65.2)	0.007
Diabetic Neuropathy	212 (1.63)	181 (1.39)	0.020
Macrovascular Complications			
Heart Failure	396 (3.04)	294 (2.26)	0.049
Acute Myocardial Infarct	398 (3.05)	331 (2.54)	0.031
Stroke/ Transient Ischemic Attack	402 (3.09)	394 (3.02)	0.004
Atrial Fibrillation	394 (3.02)	243 (1.87)	0.075
Other Comorbidities			
Hyperlipidemia	416 (3.19)	332 (2.55)	0.039
Hypertension	3242 (24.9)	2947 (22.6)	0.053
Immune Mediated Enterocolitis	714 (5.48)	617 (4.74)	0.034
Other Cancer	286 (2.20)	308 (2.36)	0.011
Anti-Diabetic and Lipid-Lowering Medications			
Metformin	12133 (93.1)	12202 (93.7)	0.021
Sulphonylurea	10282 (78.9)	10649 (81.7)	0.071
Insulin	6240 (47.9)	5645 (43.3)	0.092
Acarbose	374 (2.87)	342 (2.62)	0.015
Thiazolidinedione	2843 (21.8)	2470 (19.0)	0.071
Glucagon-Like-Peptide Agonist	240 (1.84)	146 (1.12)	0.060
Statins	9915 (76.1)	9636 (74.0)	0.049
Complete Blood Count			
Red Cell Count	4.70 (0.58)	4.52 (0.689)	0.276
Mean Corpuscular Volume	87.0 (7.25)	87.0 (7.77)	0.005
Mean Corpuscular Hemoglobin Concentration	29.3 (2.89)	29.4 (3.13)	0.049
White Cell Count	7.89 (2.55)	8.07 (2.92)	0.066
Neutrophil	5.06 (2.35)	5.42 (2.92)	0.135
Lymphocyte	2.13 (0.956)	1.97 (0.802)	0.179
Neutrophil to Lymphocyte Ratio	2.97 (3.63)	3.68 (4.82)	0.164
Eosinophil	0.212 (0.185)	0.211 (0.217)	0.008
Platelet	242 (67.7)	243 (72.6)	0.012
Platelet to Lymphocyte Ratio	134 (176)	148 (144)	0.089
Renal Function Test			
Sodium	139.2 (2.75)	139.2 (2.90)	<0.001
Potassium	4.31 (0.44)	4.34 (0.481)	0.055
Urea	5.72 (1.96)	6.34 (3.53)	0.216
Creatinine	78.7 (28.3)	92.9 (87.9)	0.217
Estimated Glomerular Filtration Rate	83.4 (22.2)	78.6 (26.5)	0.196
Liver Function Test			
Alkaline Phosphatase	74.2 (26.8)	78.1 (33.4)	0.126
Aspartate Transaminase	28.0 (29.0)	27.8 (34.8)	0.007
Alanine Transaminase	31.5 (29.9)	29.3 (31.8)	0.073
Bilirubin	11.6 (6.27)	11.4 (6.21)	0.028
Protein	74.4 (4.95)	73.5 (5.54)	0.165
Albumin	42.5 (3.28)	41.6 (4.08)	0.230
Lipid Profile			
Triglyceride	1.72 (1.64)	1.68 (1.40)	0.026
Total Cholesterol	4.31 (0.990)	4.39 (0.971)	0.080
High-Density Lipoprotein	1.18 (0.315)	1.20 (0.326)	0.079
Low-Density Lipoprotein	2.38 (0.790)	2.44 (0.800)	0.084
Glucose Control			
Glycated Hemoglobin	8.06 (1.72)	8.06 (1.71)	0.003
Fasting Blood Glucose	9.02 (3.52)	8.99 (4.15)	0.007

Outcomes			
Death		346 (2.66)	1062 (8.15)
Incident CRC		65 (0.499)	118 (0.906)

Table 1: Baseline Demographics of SGLT2i and DPP4i Users after Propensity Score Matching

	Person-Years	Number of Event	IR [95% CI]	IRR [95% CI]
Before Propensity Score Matching				
Overall	252767	471	1.86 [1.70-2.04]	-
DPP4i Users	159796.7	377	2.36 [2.13-2.61]	-
SGLT2i Users	92970.32	94	1.01 [0.817-1.24]	0.429 [0.342-0.537]
After Propensity Score Matching				
Overall	117734.1	183	1.55 [1.34- 1.80]	-
DPP4i Users	58083.66	118	2.03 [1.68-2.43]	-
SGLT2i Users	59650.41	65	1.09 [0.841-1.39]	0.566 [0.418-0.766]

Table 2: Annualized Incidence Rate of CRC per 1000 Person-Year before and after Propensity Score Matching.

	Hazard ratios	95% CI	P-value
Before Propensity Score Matching			
Model 1	0.424	0.338-0.531	<0.001
Model 2	0.599	0.474-0.760	<0.001
Model 3	0.599	0.474-0.759	<0.001
Model 4	0.579	0.444-0.758	<0.001
Model 5	0.588	0.449-0.769	<0.001
Model 6	0.572	0.431-0.759	0.001
After Propensity Score Matching			
Model 1	0.531	0.392-0.719	<0.001
Model 2	0.548	0.405-0.742	<0.001
Model 3	0.548	0.405-0.742	<0.001
Model 4	0.537	0.397-0.728	<0.001
Model 5	0.535	0.395-0.725	<0.001
Model 6	0.526	0.382-0.724	<0.001

Table 3: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of medications, comorbidities, and HDL.

	Hazard ratios	95% CI	P-value
Male			
Model 1	0.467	0.314-0.692	<0.001
Model 2	0.481	0.324-0.714	<0.001
Model 3	0.480	0.323-0.713	<0.001
Model 4	0.481	0.324-0.715	<0.001
Model 5	0.478	0.322-0.710	<0.001
Model 6	0.461	0.303-0.702	<0.001
Female			
Model 1	0.639	0.398-1.03	0.064
Model 2	0.481	0.324-0.714	0.097
Model 3	0.670	0.417-1.08	0.098
Model 4	0.624	0.388-1.01	0.053
Model 5	0.624	0.387-1.01	0.053
Model 6	0.616	0.374-1.01	0.056

Table 4: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching in Patient Subgroup Stratified by Gender

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age. Model 3: Adjusted for age and HbA1c. Model 4: Adjusted for age, HbA1c and use of other medications. Model 5: Adjusted for age, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, HbA1c, use of other medications, comorbidities and HDL.

	Hazard ratios	95% CI	P-value
Subjects < 65 Years Old			
Model 1	0.347	0.210-0.692	<0.001
Model 2	0.341	0.206-0.562	<0.001
Model 3	0.341	0.207-0.562	<0.001
Model 4	0.321	0.194-0.530	<0.001
Model 5	0.321	0.195-0.531	<0.001
Model 6	0.294	0.174-0.496	<0.001
Subject ≥ 65 Years Old			
Model 1	0.727	0.493-1.07	0.107
Model 2	0.738	0.501-1.09	0.126
Model 3	0.737	0.500-1.09	0.124
Model 4	0.735	0.498-1.09	0.122
Model 5	0.722	0.489-1.07	0.102
Model 6	0.767	0.505-1.16	0.211

Table 5: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching in Patient Subgroup Stratified by Age

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of other medications, comorbidities and HDL.

	Hazard ratios	95% CI	P-value
eGFR ≥ 45mL/min/ 1.73m²			
Model 1	0.474	0.359-0.624	<0.001
Model 2	0.605	0.454-0.807	<0.001
Model 3	0.605	0.454-0.807	<0.001
Model 4	0.570	0.409-0.795	<0.001
Model 5	0.580	0.416-0.809	0.001
Model 6	0.560	0.395-0.792	0.001
eGFR < 45mL/min/ 1.73m²			
Model 1	0.480	0.177-1.31	0.151
Model 2	0.549	0.201-1.50	0.243
Model 3	0.551	0.202-1.51	0.245
Model 4	0.472	0.158-1.41	0.178
Model 5	0.480	0.161-1.44	0.189
Model 6	0.524	0.173-1.59	0.253

Table 6: Univariable and Multivariable Cause-Specific Cox Regression before Propensity Score Matching in Patient Subgroup Stratified by eGFR

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of medications, comorbidities and HDL.